Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06056011 · ClinicalTrials.gov registry record · NA
Timmy3 Module Clinical Accuracy ISO 80601-2-56:2017 + A1 2018
A NA study, sponsored by Baxter Healthcare Corporation.
- Completed
- Registry status
- NA
- Development phase
- 373
- Enrollment target
NCT06056011: Completed NA study, sponsored by Baxter Healthcare Corporation.
NCT06056011 is a NA study that has completed, run by Baxter Healthcare Corporation. The registered enrollment target is 373 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06056011, a NA study, has completed, sponsored by Baxter Healthcare Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 373 participants
- Enrollment target
Study Summary
The purpose of this document is to validate the clinical accuracy of the TIMMY3 thermometry module, integrated into host device CVSM, according to ISO 80601-2-56:2017 + A1 2018.
Primary Outcome
Clinical bias is the mean difference between the first device under test (DUT) output temperature (T1) and the corresponding reference clinical thermometer (TRCT) within the ISO-compliant analysis set and age group, calculated per ISO 80601-2-56:2017 + A1:2018 (refer to ISO formula \[2\]).
Interventions
- DEVICE Connex CVSM with Timmy3 module
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 373 participants |
| Start Date | 2024-02-19 |
| Est. Completion | 2025-03-18 |
| Phase | NA |
What the finished NCT06056011 record still lists
NCT06056011 is an interventional study that assigns participants to a tested intervention. The registered 373 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (73% lower).
The record links to 0 conditions, and to 1 intervention - of which Connex CVSM with Timmy3 module is the first listed.
NCT06056011 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06056011 about?
NCT06056011 is a clinical study titled "Timmy3 Module Clinical Accuracy ISO 80601-2-56:2017 + A1 2018". The purpose of this document is to validate the clinical accuracy of the TIMMY3 thermometry module, integrated into host device CVSM, according to ISO 80601-2-56:2017 + A1 2018.
What is the current status of trial NCT06056011?
This trial is currently completed. It is a NA study. The enrollment target is 373 participants. The study started on 2024-02-19. Estimated completion is 2025-03-18.
What interventions are being tested in trial NCT06056011?
The interventions under investigation include: Connex CVSM with Timmy3 module (DEVICE).
Who is sponsoring clinical trial NCT06056011?
This trial is sponsored by Baxter Healthcare Corporation, which has 46 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06056011's enrollment target sits among peer trials
373 280th of 2000 higher than 1,721 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07276750 · 373 participants · NA
Coaching and Leadership in Autism Support Settings
- NCT04801589 · 372 participants · Phase 3
Goal-Directed Sedation in Mechanically Ventilated Infants and Children
- NCT04879329 · 372 participants · Phase 2
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
- NCT05318105 · 372 participants · NA
Ultrafiltration Versus IV Diuretics in Worsening Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI